Dave Manan, Shrimali Lalit, Agarwal Ankit


Background - Lung cancer is a major cause of cancer-related mortality. About 85% of cases are related to cigarette smoking. CEA was one of the tumour markers use to evaluate lung cancer, also elevated levels are seen in 40–80% of patients with lung cancer, showing a high sensitivity for adenocarcinoma and for advanced stage studies show that CEA level in serum is significantly increasing in patients with lung cancer. Serum CEA level can be used as a sensitive and specific screening test for various cancers including lung cancer.

Method - 74 patients were studied at Geetanjali Hospital, Udaipur. Only biopsy proven cases of carcinoma lung were interviewed and demographic data such as age, sex & addiction history were noted.

Results - Among 74 patients diagnosed with lung cancer highest cases were seen in patients with Adenocarcinoma 38 (51.35%) followed by Squamous cell carcinoma with 26 (35.14%) followed by Small cell carcinoma 10 (13.51%). 27 (71.05%) out of 38 patients of adenocarcinoma, 10 (38.48%) out of 26 patients of Squamous cell carcinoma and 6 (60%) out of 10 patients of small cell carcinoma showed CEA values more than normal. 30 (71.43%) patients out of 42 of stage IV, all 5 patients of stage IIIB 4 (57.14%) Out of 7 of IIIA patients 2 (28.57%) out of 7 patients of both stages IIA & IIB showed higher CEA level than normal. Higher than normal level of CEA was seen in all 3 (100%) patients of pleural metastasis followed by brain metastasis was seen in 5 (83.33%) out of 6 patients, liver metastasis was seen in 5 (71.43%)  out of 7 patients, adrenal metastasis was seen in 6 (60%)  out of 10 patients, bone metastasis was seen in 4 (57.14%)  out of 7 patients showed higher than normal level of CEA.

Conclusion- This observation highlights the importance of tumour markers in relation to histological type and tumour staging. Routine serum CEA testing in patients with Nonsmall cell lung carcinoma than Small cell Lung Carcinoma, allows the identification of a significant proportion of patients at high risk of developing a tumour relapse being cost effective.


Lung cancer, Carcinoembryonic antigen levels

Full Text:



Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. SeminRoentgenol 2005;40:90-7.

Pamies, R.J. and Crawford, D.R. (1996). Tumour markers: an update Med. Clin. North Am. 80,185-199.

Gold P, Freedman So. Demonstration of Tumour-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques. J Exp Med 1965 Mar 1;121:439–462

Buccheri And Ferrigno et al, Identifying Patients at Risk of Early PostoperativeRecurrence of Lung Cancer: A New Use of the Old CEATest AnnThoracSurg 2003;75:973–80

Stevens DP, Mackay IR. Increased carcinoembryonic antigen in heavy cigarette smokers. Lancet 1973;2:1238–9.

Oscar Arrieta, Cynthia Villarreal Garza et al,Usefulness Of Serum carcinoembryonic Antigen(Cea) In Evaluating Response To Chemotherapy In Patients With Advanced Non Small-Cell Lung Cancer: A Prospective Cohort Study, Bmc Cancer 2013, 13:254

Konstantinos Charalabopoulos,1 AgathiKarakosta et al CEA Levels in Serum and BAL in Patients Suffering from Lung Cancer Correlation with Individuals Presenting Benign Lung Lesions and Healthy Volunteers, Medical Oncology,vol. 24, no. 2, 219–225, 2007

Jae Jun Kim, M.D.1, KwanyongHyun,The Significance of Serum Carcinoembryonic Antigen in Lung Adenocarcinoma, Korean J Thorac Cardiovasc Surg 2015;48:335-344

Feng Chen, Jia Li, Diagnostic value of CYFRA 21‑1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease, Journal of Cancer Research and Therapeutics – Vol.14 (2);2018

Zaleska M, Szturmowicz M, Zych J, Sliz B, Demkow U, Langfort R, et al. Elevatedserum NSE in inoperable non-small-cell lung carcinoma (NSCLC) Is associated with a better response but worse prognosis. PneumonolAlergol Pol2010;78(1):14–20

Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodoma T,et al: Enzyme immunoassay of immunoreactive progastrin- releasing peptide(31–98) as tumor marker for small cell lung carcinoma: development and evaluation. ClinChem 1995;41: 537–543

Ahmet Ursavas, Mehmet Karadag Et Al Serum Carcinoembryonicantigen Level As A Predictive Marker For Distant metastasis In Non-Small Cell Lung Cancer,Eur J Gen Med 2007;4(3):107-114

Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC cancer. 2009 Dec;9(1):119

Concannon JP, Dalbow MH, Hodgson SE, et al. Prognostic value of preoperative carcinoembryonic antigen (CEA) in patients with bronchogenic carcinoma. Cancer 1978;42:1477-83

Yuan Gao,PingPing Song et al, Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations,Gao et al BMC cancer,2017,17:484

Jiasi Wang,Yanpeng Chu et al,The clinical value of carcinoembryonic antigen for tumor metastasis assessment in lung cancer,2019,PeerJ 7:e7433

Reck M,Popat S et al, Metastatic non-small cell lung cancer(NSCLC):ESMOclinical practice guidelines for diagnosis, treatment and follow up. Annals of Oncology 25(Suppl 3):iii27-iii39


  • There are currently no refbacks.